Differentiation Between Luminal-A and Luminal-B Breast Cancer Using Intravoxel Incoherent Motion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Publication date: Available online 1 August 2017
Source:Academic Radiology
Author(s): Hiroko Kawashima, Tosiaki Miyati, Naoki Ohno, Masako Ohno, Masafumi Inokuchi, Hiroko Ikeda, Toshifumi Gabata
Rationale and ObjectivesThe study aimed to investigate whether intravoxel incoherent motion (IVIM) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) can differentiate luminal-B from luminal-A breast cancerMaterials and MethodsBiexponential analyses of IVIM and DCE MRI were performed using a 3.0-T MRI scanner, involving 134 patients with 137 pathologically confirmed luminal-type invasive breast cancers. Luminal-type breast cancer was categorized as luminal-B breast cancer (LBBC, Ki-67 ≧ 14%) or luminal-A breast cancer (LABC, Ki-67 < 14%). Quantitative parameters from IVIM (pure diffusion coefficient [D], perfusion-related diffusion coefficient [D*], and fraction [f]) and DCE MRI (initial percentage of enhancement and signal enhancement ratio [SER]) were calculated. The apparent diffusion coefficient (ADC) was also calculated using monoexponential fitting. We correlated these data with the Ki-67 status.ResultsThe D and ADC values of LBBC were significantly lower than those of LABC (P = 0.028, P = 0.037). The SER of LBBC was significantly higher than that of LABC (P = 0.004). A univariate analysis showed that a significantly lower D (<0.847 x 10⁻³ mm²/s), lower ADC (<0.960 × 10⁻³ mm²/s), and higher SER (>1.071) values were associated with LBBC (all P values <0.01), compared to LABC. In a multivariate analysis, a higher SER (>1.071; odds ratio: 3.0099, 95% confidence interval: 1.4246–6.3593; P = 0.003) value and a lower D (<0.847 × 10⁻³ mm²/s; odds ratio: 2.6878, 95% confidence interval: 1.0445–6.9162; P = 0.040) value were significantly associated with LBBC, compared to LABC.ConclusionThe SER derived from DCE MRI and the D derived from IVIM are associated independently with the Ki-67 status in patients with luminal-type breast cancer.



http://ift.tt/2w6j9pm